This mobile application was created to facilitate enrollment into the ATACH-II Clinical Trial. ATACH-II is a five-year clinical trial designed to determine the efficacy of early, intensive antihypertensive treatment in stroke patients.
The primary hypothesis of this trial is that treating hemorrhagic stoke survivors with intensive blood pressure reduction therapy will reduce the proportion of death and disability at 3 months by 10% or greater compared with the group treated with the standard blood pressure reduction therapy.